Improving colonoscopy follow-up after abnormal FIT
Part of Cancer, Digestive system clinical trials.
This trial tests a program to help people who had an abnormal FIT stool test follow through with getting a colonoscopy. The goal is to improve cancer screening by providing extra support through a care team and technology.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You had a positive (abnormal) FIT stool test.
- You are 18 years old or older.
- You speak English, Spanish, or Cantonese.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a way to help people get recommended colorectal cancer screenings. If you are 45–75 and due for screening, you may receive information or support to help you decide and get tested.
This trial checks a stool test called FIT-DNA after colorectal (colon) cancer surgery. It aims to see whether this test can help doctors monitor for recurrence during follow-up and decide how closely to watch.
This study tests if a more straightforward screening process can work better for people referred with possible colon cancer symptoms. It looks at how a positive stool test (FIT) leads to a diagnosis.
This trial compares different ways to screen healthy adults aged 45–74 for colorectal cancer using non-invasive tests. If you join, you will help find the best method to catch cancer early and prevent it.
This trial is testing a new way to screen for colorectal cancer in adults aged 45 to 74. If you join, you will help researchers find better methods for early detection.
This study tests a mobile app designed to help improve the quality of colonoscopies for people in a colorectal cancer screening program. If you have had a positive FIT test and are between 50 and 69, you may be able to join.
Hear when a new Colon Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.